All In Biotech

Drug Trial Radar · NCT02672332

P3 Study in Acne Comparing Once Daily SB204 and Vehicle

A Phase 3 Multi-Center, Randomized, Double-Blinded, Vehicle-Controlled, Parallel Group Study Comparing the Efficacy, Tolerability and Safety of SB204 and Vehicle Gel Once Daily in the Treatment of Acne Vulgaris

Last checked: Nov 19, 2026Latest source record: Jul 24, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,307 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,307

Actual

Start

Feb 22, 2016

Primary completion

Dec 2016

Study completion Dec 21, 2016

Sponsor

Lead sponsor
Novan, Inc.Industry
Sponsor type
Industry
Collaborators
Chiltern International Inc.
First posted
Feb 3, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 9 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a 12 week, multi-center, double-blinded, randomized, vehicle-controlled, parallel group, study to be conducted in approximately 1300 subjects with acne vulgaris in the US.

Conditions

  • Acne Vulgaris

Interventions

  • SB204 4%Drug

    Once daily

  • Vehicle GelDrug

    Placebo comparator

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Absolute Change From Baseline in Inflammatory Lesion CountsTime frame: Baseline and Week 12
  2. Absolute Change From Baseline in Non-inflammatory Lesion CountsTime frame: Baseline and Week 12
  3. Proportion of Subjects With Investigator Global Assessment (IGA) Success at Week 12Time frame: Baseline and Week 12

Locations

55 sites in 1 country. Site status is shown where the registry gives one.

  • CIL #146

    Anaheim, California

  • CIL #118

    Encinitas, California

  • CIL #186

    Fresno, California

  • CIL #210

    Fresno, California

  • CIL #209

    Oceanside, California

  • CIL #161

    San Diego, California

  • CIL #113

    San Diego, California

  • CIL #199

    Santa Rosa, California

  • CIL #103

    Boca Raton, Florida

  • CIL #173

    Hialeah, Florida

  • CIL #212

    Homestead, Florida

  • CIL #222

    Lauderdale Lakes, Florida

  • CIL #157

    Miami, Florida

  • CIL #177

    North Miami Beach, Florida

  • CIL #150

    Orlando, Florida

  • CIL #172

    Orlando, Florida

  • CIL #203

    Ormond Beach, Florida

  • CIL #211

    South Miami, Florida

  • CIL #229

    Tampa, Florida

  • CIL #153

    Wellington, Florida

  • Cil # 179

    Chicago, Illinois

  • CIL #215

    Wichita, Kansas

  • CIL #117

    Louisville, Kentucky

  • CIL #180

    New Orleans, Louisiana

  • CIL #205

    Glenn Dale, Maryland

  • CIL #230

    Quincy, Massachusetts

  • CIL #112

    Detroit, Michigan

  • CIL #149

    Troy, Michigan

  • CIL #225

    Saint Joseph, Missouri

  • CIL #187

    St Louis, Missouri

  • CIL #140

    Omaha, Nebraska

  • CIL #182

    Las Vegas, Nevada

  • CIL #201

    Berlin, New Jersey

  • CIL #141

    Montclair, New Jersey

  • CIL #156

    Albuquerque, New Mexico

  • CIL #107

    New York, New York

  • CIL #108

    Rochester, New York

  • CIL #104

    Stony Brook, New York

  • CIL #193

    High Point, North Carolina

  • CIL #166

    Winston-Salem, North Carolina

Showing 40 of 55 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.